Skip to main content

Table 3 When the total antibody is positive, the change in the number of symptomatic and asymptomatic positive patients with and without underlying disease

From: Seroprevalence and dynamics of anti-SARS-CoV-2 antibodies: a longitudinal study based on patients with underlying diseases in Wuhan

Total antibody positive (No.)

Underlying disease (No.)

IgA + (%)

IgM + (%)

IgG + (%)

Nabs + (%)

Baseline

 Symptomatic (65)

Yes (23)

5 (21.74%)

0 (0.00%)

23 (100.00%)

14 (60.87%)

No (42)

7 (16.67%)

3 (7.14%)

42 (100.00%)

24 (57.14%)

 Asymptomatic (248)

Yes (74)

17 (22.97%)

7 (9.46%)

74 (100.00%)

29 (39.19%)

No (174)

36 (20.69%)

23 (13.22%)

174 (100.00%)

68 (39.08%)

First follow-up

 Symptomatic (56)

Yes (20)

3 (15.00%)

0 (0.00%)

20 (100.00%)

15 (75.00%)

No (36)

3 (8.33%)

1 (2.78%)

36 (100.00%)

22 (61.11%)

 Asymptomatic (156)

Yes (46)

8 (17.39%)

1 (2.17%)

46 (100.00%)

20 (43.48%)

No (110)

13 (11.82%)

3 (2.73%)

109 (99.09%)

45 (40.91%)

Second follow-up

 Symptomatic (60)

Yes (20)

0 (0.00%)

0 (0.00%)

19 (95.00%)

13 (65.00%)

No (40)

0 (0.00%)

0 (0.00%)

39 (97.50%)

27 (67.50%)

 Asymptomatic (178)

Yes (48)

6 (12.50%)

1 (2.08%)

44 (91.67%)

23 (47.92%)

No (130)

11 (8.46%)

3 (2.31%)

129(99.23%)

61(46.92%)

  1. Nabs neutralising antibody titres